Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease.
Adult
Aged
Alcoholism
/ blood
Biomarkers
/ blood
Chromatography, High Pressure Liquid
Chromatography, Reverse-Phase
Fatty Acids, Omega-3
/ blood
Fatty Acids, Omega-6
/ blood
Feces
/ chemistry
Female
Hepatitis, Alcoholic
/ blood
Humans
Male
Metabolomics
/ methods
Middle Aged
Oxylipins
/ blood
Spectrometry, Mass, Electrospray Ionization
Tandem Mass Spectrometry
AA
DHA
EPA
Lipid mediator
Metabolomics
PUFA
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
27
03
2019
accepted:
20
04
2019
pubmed:
12
5
2019
medline:
24
12
2019
entrez:
12
5
2019
Statut:
ppublish
Résumé
Alcohol-related liver disease is one of the most prevalent chronic liver diseases worldwide. Mechanisms involved in the pathogenesis of alcohol-related liver disease are not well understood. Oxylipins play a crucial role in numerous biological processes and pathological conditions. Nevertheless, oxylipins are not well studied in alcohol-related liver disease. (1) To characterize the patterns of bioactive ω-3 and ω-6 polyunsaturated fatty acid metabolites in alcohol use disorder and alcoholic hepatitis patients and (2) to identify associations of serum oxylipins with clinical parameters in patients with alcohol-related liver disease. We performed a comprehensive liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis of serum and fecal oxylipins derived from ω-6 arachidonic acid, ω-3 eicosapentaenoic acid, and docosahexaenoic acid in a patient cohort with alcohol-related liver disease. Our results show profound alterations in the serum oxylipin profile of patients with alcohol use disorder and alcoholic hepatitis compared to nonalcoholic controls. Spearman correlation of the oxylipins with clinical parameters shows a link between different serum oxylipins and intestinal permeability, aspartate aminotransferase, bilirubin, albumin, international normalized ratio, platelet count, steatosis, fibrosis and model for end-stage liver disease score. Especially, higher level of serum 20-HETE was significantly associated with decreased albumin, increased hepatic steatosis, polymorphonuclear infiltration, and 90-day mortality. Patients with alcohol-related liver disease have different oxylipin profiles. Future studies are required to confirm oxylipins as disease biomarker or to connect oxylipins to disease pathogenesis.
Sections du résumé
BACKGROUND
Alcohol-related liver disease is one of the most prevalent chronic liver diseases worldwide. Mechanisms involved in the pathogenesis of alcohol-related liver disease are not well understood. Oxylipins play a crucial role in numerous biological processes and pathological conditions. Nevertheless, oxylipins are not well studied in alcohol-related liver disease.
AIMS
(1) To characterize the patterns of bioactive ω-3 and ω-6 polyunsaturated fatty acid metabolites in alcohol use disorder and alcoholic hepatitis patients and (2) to identify associations of serum oxylipins with clinical parameters in patients with alcohol-related liver disease.
METHODS
We performed a comprehensive liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis of serum and fecal oxylipins derived from ω-6 arachidonic acid, ω-3 eicosapentaenoic acid, and docosahexaenoic acid in a patient cohort with alcohol-related liver disease.
RESULTS
Our results show profound alterations in the serum oxylipin profile of patients with alcohol use disorder and alcoholic hepatitis compared to nonalcoholic controls. Spearman correlation of the oxylipins with clinical parameters shows a link between different serum oxylipins and intestinal permeability, aspartate aminotransferase, bilirubin, albumin, international normalized ratio, platelet count, steatosis, fibrosis and model for end-stage liver disease score. Especially, higher level of serum 20-HETE was significantly associated with decreased albumin, increased hepatic steatosis, polymorphonuclear infiltration, and 90-day mortality.
CONCLUSIONS
Patients with alcohol-related liver disease have different oxylipin profiles. Future studies are required to confirm oxylipins as disease biomarker or to connect oxylipins to disease pathogenesis.
Identifiants
pubmed: 31076986
doi: 10.1007/s10620-019-05638-y
pii: 10.1007/s10620-019-05638-y
pmc: PMC6588282
mid: NIHMS1529125
doi:
Substances chimiques
Biomarkers
0
Fatty Acids, Omega-3
0
Fatty Acids, Omega-6
0
Oxylipins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1878-1892Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA020703
Pays : United States
Organisme : BLRD VA
ID : I01 BX004594
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA024726
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA021856
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA026939
Pays : United States
Références
Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18.
doi: 10.1038/ajg.2016.517
pubmed: 27995906
Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141:1572–1585.
doi: 10.1053/j.gastro.2011.09.002
pubmed: 21920463
pmcid: 3214974
Gabbs M, Leng S, Devassy JG, Monirujjaman M, Aukema HM. Advances in our understanding of oxylipins derived from dietary PUFAs. Adv Nutr (Bethesda, Md.). 2015;6:513–540.
doi: 10.3945/an.114.007732
Buczynski MW, Dumlao DS, Dennis EA. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res. 2009;50:1015–1038.
doi: 10.1194/jlr.R900004-JLR200
pubmed: 19244215
pmcid: 2681385
Arnold C, Konkel A, Fischer R, Schunck W-H. Cytochrome P450–dependent metabolism of ω-6 and ω-3 long-chain polyunsaturated fatty acids. Pharmacol Rep. 2010;62:536–547.
doi: 10.1016/S1734-1140(10)70311-X
Barquissau V, Ghandour RA, Ailhaud G, et al. Control of adipogenesis by oxylipins, GPCRs and PPARs. Biochimie. 2017;136:3–11.
doi: 10.1016/j.biochi.2016.12.012
pubmed: 28034718
Caligiuri SPB, Parikh M, Stamenkovic A, Pierce GN, Aukema HM. Dietary modulation of oxylipins in cardiovascular disease and aging. Am J Physiol Heart Circ Physiol. 2017;313:H903–H918.
doi: 10.1152/ajpheart.00201.2017
pubmed: 28801523
Tourdot BE, Ahmed I, Holinstat M. The emerging role of oxylipins in thrombosis and diabetes. Front Pharmacol. 2014;4:176.
doi: 10.3389/fphar.2013.00176
pubmed: 24432004
pmcid: 3882718
Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871.
doi: 10.1126/science.294.5548.1871
Yeung J, Hawley M, Holinstat M. The expansive role of oxylipins on platelet biology. J Mol Med (Berlin, Germany). 2017;95:575–588.
doi: 10.1007/s00109-017-1542-4
Wagner D, Westover K, Simmons DL. Nonsteroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever. Clin Infect Dis. 2000;31:S211–S218.
doi: 10.1086/317517
pubmed: 11113025
Liu MC, Dubé LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996;98:859–871.
doi: 10.1016/S0091-6749(96)80002-9
pubmed: 8939149
Zhang W, Zhong W, Sun Q, Sun X, Zhou Z. Hepatic overproduction of 13-HODE due to ALOX15 upregulation contributes to alcohol-induced liver injury in mice. Sci Rep. 2017;7:8976.
doi: 10.1038/s41598-017-02759-0
pubmed: 28827690
pmcid: 5567196
Feldstein AE, Lopez R, Tamimi TA-R, et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010;51:3046–3054.
doi: 10.1194/jlr.M007096
pubmed: 20631297
pmcid: 2936759
Ball SA, Tennen H, Poling JC, Kranzler HR, Rounsaville BJ. Personality, temperament, and character dimensions and the DSM-IV personality disorders in substance abusers. J Abnorm Psychol. 1997;106:545–553.
doi: 10.1037/0021-843X.106.4.545
pubmed: 9358685
Brandl K, Hartmann P, Jih LJ, et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018;69:396–405.
doi: 10.1016/j.jhep.2018.03.031
pubmed: 29654817
pmcid: 6054564
Nguyen-Khac E, Thiele M, Voican C, et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:614–625.
doi: 10.1016/S2468-1253(18)30124-9
pubmed: 29983372
Salavrakos M, Piessevaux H, Komuta M, Lanthier N, Starkel P. Fibroscan reliably rules out advanced liver fibrosis and significant portal hypertension in alcoholic patients. J Clin Gastroenterol. 2018. https://doi.org/10.1097/MCG.0000000000001119 .
doi: 10.1097/MCG.0000000000001119
pubmed: 30106835
Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. Int J Endocrinol. 2015;2015:343828.
doi: 10.1155/2015/343828
pubmed: 26064107
pmcid: 4430647
Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Gastroenterology. 2019;156:1717–1730.
doi: 10.1053/j.gastro.2019.01.042
pubmed: 30689971
Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348–1359.
doi: 10.1002/hep.29639
pubmed: 29108123
pmcid: 5867216
Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022–1030.
doi: 10.1016/j.jhep.2016.12.022
pubmed: 28039099
Leclercq S, Matamoros S, Cani PD, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA. 2014;111:E4485–E4493.
doi: 10.1073/pnas.1415174111
pubmed: 25288760
Shearer GC, Harris WS, Pedersen TL, Newman JW. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J Lipid Res. 2010;51:2074–2081.
doi: 10.1194/jlr.M900193-JLR200
pubmed: 19671931
pmcid: 2903824
Luria A, Weldon SM, Kabcenell AK, et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem. 2007;282:2891–2898.
doi: 10.1074/jbc.M608057200
pubmed: 17135253
Barupal DK, Fiehn O. Chemical similarity enrichment analysis (ChemRICH) as alternative to biochemical pathway mapping for metabolomic datasets. Sci Rep. 2017;7:14567.
doi: 10.1038/s41598-017-15231-w
pubmed: 29109515
pmcid: 5673929
Warner DR, Liu H, Ghosh Dastidar S, et al. Ethanol and unsaturated dietary fat induce unique patterns of hepatic ω-6 and ω-3 PUFA oxylipins in a mouse model of alcoholic liver disease. PloS One. 2018;13:e0204119.
doi: 10.1371/journal.pone.0204119
pubmed: 30256818
pmcid: 6157879
Lazic M, Inzaugarat ME, Povero D, et al. Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis. PloS one. 2014;9:e107658.
doi: 10.1371/journal.pone.0107658
pubmed: 25251155
pmcid: 4175074
Puri P, Xu J, Vihervaara T, et al. Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese. J Lipid Res. 2016;57:1017–1028.
doi: 10.1194/jlr.M066175
pubmed: 27020313
pmcid: 4878186
Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.). 2009;50:1827–1838.
doi: 10.1002/hep.23229
Zein CO, Lopez R, Fu X, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (Baltimore, Md.). 2012;56:1291–1299.
doi: 10.1002/hep.25778
Kirpich IA, Feng W, Wang Y, et al. The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res. 2012;36:835–846.
doi: 10.1111/j.1530-0277.2011.01673.x
pubmed: 22150547
Noverr MC, Erb-Downward JR, Huffnagle GB. Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes. Clin Microbiol Rev. 2003;16:517–533.
doi: 10.1128/CMR.16.3.517-533.2003
pubmed: 12857780
pmcid: 164223
Tsitsigiannis DI, Keller NP. Oxylipins as developmental and host–fungal communication signals. Trends Microbiol. 2007;15:109–118.
doi: 10.1016/j.tim.2007.01.005